Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases
Erkrankungsgruppe:
Sonstiges
Organsystem:
Blut
Stadium:
Ersterkrankung
Standort:
Essen
EudraCT:
2013-005508-33
Prüfplan-Code:
MC-FludT.16/NM
Phase:
II
Prüfsubstanz:
Treosulfan, Busilvex
Sponsor:
medac Gesellschaft für klinische Spezialpräparate mbH